{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:16:11Z","timestamp":1768821371061,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pancreatic ductal adenocarcinoma (PDAC) patients have poor prognosis and poor response to treatment. This is largely due to PDAC being associated with a dense and active stroma and tumor fibrosis (desmoplasia). Desmoplasia is characterized by excessive degradation and formation of the extracellular matrix (ECM) generating collagen fragments that are released into circulation. We evaluated the association of specific collagen fragments measured in pre-treatment serum with outcome in patients with PDAC. Matrix metalloprotease (MMP)-degraded type I collagen (C1M), type III collagen (C3M), type IV collagen (C4M) and a pro-peptide of type III collagen (PRO-C3) were measured by ELISA in pre-treatment serum from a randomized phase 3 clinical trial of patients with stage III\/IV PDAC treated with 5-fluorouracil based therapy (n\u2009=\u2009176). The collagen fragments were evaluated for their correlation (r, Spearman) with serum CA19-9 and for their association with overall survival (OS) based on Cox-regression analyses. In this phase 3 PDAC trial, pre-treatment serum collagen fragment levels were above the reference range for 67%-98% of patients, with median values in PDAC approximately two-fold higher than reference levels. Collagen fragment levels did not correlate with CA19-9 (r\u2009=\u20090.049\u20130.141,<jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>ns<\/jats:italic>). On a continuous basis, higher levels of all collagen fragments were associated with significantly shorter OS. When evaluating degradation (C3M) and formation (PRO-C3) of type III collagen further, higher PRO-C3 was associated with poor OS (&gt;25<jats:sup>th<\/jats:sup>percentile cut-point, HR\u2009=\u20092.01, 95%CI\u2009=\u20091.33\u20133.05) and higher C3M\/PRO-C3 ratio was associated with improved OS (&gt;25<jats:sup>th<\/jats:sup>percentile cut-point, HR\u2009=\u20090.53, 95%CI\u2009=\u20090.34\u20130.80). When adjusting for CA19\u20139 and clinical covariates, PRO-C3 remained significant (HR\u2009=\u20091.65, 95%CI\u2009=\u20091.09\u20132.48). In conclusion, collagen remodeling quantified in pre-treatment serum as a surrogate measure of desmoplasia was significantly associated with OS in a phase 3 clinical PDAC trial, supporting the link between desmoplasia, tumorigenesis, and response to treatment. If validated, these biomarkers may have prognostic and\/or predictive potential in future PDAC trials.<\/jats:p>","DOI":"10.1038\/s41598-019-56268-3","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T11:02:32Z","timestamp":1577185352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Nicholas","family":"Willumsen","sequence":"first","affiliation":[]},{"given":"Suhail M.","family":"Ali","sequence":"additional","affiliation":[]},{"given":"Kim","family":"Leitzel","sequence":"additional","affiliation":[]},{"given":"Joseph J.","family":"Drabick","sequence":"additional","affiliation":[]},{"given":"Nelson","family":"Yee","sequence":"additional","affiliation":[]},{"given":"Hyma V.","family":"Polimera","sequence":"additional","affiliation":[]},{"given":"Vinod","family":"Nagabhairu","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Krecko","sequence":"additional","affiliation":[]},{"given":"Ayesha","family":"Ali","sequence":"additional","affiliation":[]},{"given":"Ashok","family":"Maddukuri","sequence":"additional","affiliation":[]},{"given":"Prashanth","family":"Moku","sequence":"additional","affiliation":[]},{"given":"Aamnah","family":"Ali","sequence":"additional","affiliation":[]},{"given":"Joyson","family":"Poulose","sequence":"additional","affiliation":[]},{"given":"Harry","family":"Menon","sequence":"additional","affiliation":[]},{"given":"Neha","family":"Pancholy","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,12,24]]},"reference":[{"key":"56268_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA. Cancer J. Clin. 68, 7\u201330 (2018).","journal-title":"CA. Cancer J. Clin."},{"key":"56268_CR2","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913\u201321 (2014).","journal-title":"Cancer Res."},{"key":"56268_CR3","doi-asserted-by":"crossref","unstructured":"Teague, A., Lim, K.-H. & Wang-Gillam, A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther. Adv. Med. Oncol. 7, 68\u201384 (2015).","DOI":"10.1177\/1758834014564775"},{"key":"56268_CR4","doi-asserted-by":"crossref","unstructured":"Adamska, A., Domenichini, A. & Falasca, M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int. J. Mol. Sci. 18 (2017).","DOI":"10.3390\/ijms18071338"},{"key":"56268_CR5","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","volume":"34","author":"EP Balaban","year":"2016","unstructured":"Balaban, E. P. et al. Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline. J. Clin. Oncol. 34, 2654\u20132667 (2016).","journal-title":"J. Clin. Oncol."},{"key":"56268_CR6","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","volume":"18","author":"C Feig","year":"2013","unstructured":"Feig, C. et al. The pancreas cancer microenvironment. Clin Cancer Res 18, 4266\u20134276 (2013).","journal-title":"Clin Cancer Res"},{"key":"56268_CR7","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","volume":"21","author":"CJ Whatcott","year":"2015","unstructured":"Whatcott, C. J. et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin. Cancer Res. 21, 3561\u20133568 (2015).","journal-title":"Clin. Cancer Res."},{"key":"56268_CR8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.18632\/genesandcancer.171","volume":"9","author":"A Cannon","year":"2018","unstructured":"Cannon, A. et al. Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. Genes Cancer 9, 78\u201386 (2018).","journal-title":"Genes Cancer"},{"key":"56268_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.21037\/jgo.2018.01.13","volume":"9","author":"A Rosenberg","year":"2018","unstructured":"Rosenberg, A. & Mahalingam, D. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. J. Gastrointest. Oncol. 9, 143\u2013159 (2018).","journal-title":"J. Gastrointest. Oncol."},{"key":"56268_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.201102147","volume":"196","author":"P Lu","year":"2012","unstructured":"Lu, P., Weaver, V. M. & Werb, Z. The extracellular matrix: a dynamic niche in cancer progression. J.Cell Biol. 196, 395\u2013406 (2012).","journal-title":"J.Cell Biol."},{"key":"56268_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/adt.2012.474","volume":"11","author":"MA Karsdal","year":"2013","unstructured":"Karsdal, M. A. et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev. Technol. 11, 70\u201392 (2013).","journal-title":"Assay Drug Dev. Technol."},{"key":"56268_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrm3904","volume":"15","author":"C Bonnans","year":"2014","unstructured":"Bonnans, C., Chou, J. & Werb, Z. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 15, 786\u2013801 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"56268_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/iep.12269","volume":"99","author":"EC Filipe","year":"2018","unstructured":"Filipe, E. C., Chitty, J. L. & Cox, T. R. Charting the unexplored extracellular matrix in cancer. Int. J. Exp. Pathol. 99, 58\u201376 (2018).","journal-title":"Int. J. Exp. Pathol."},{"key":"56268_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1067\/msy.2002.119192","volume":"131","author":"TWF Yen","year":"2002","unstructured":"Yen, T. W. F. et al. Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas. Surgery 131, 129\u201334 (2002).","journal-title":"Surgery"},{"key":"56268_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00006676-200410000-00002","volume":"29","author":"MV Apte","year":"2004","unstructured":"Apte, M. V. et al. Desmoplastic Reaction in Pancreatic Cancer. Pancreas 29, 179\u2013187 (2004).","journal-title":"Pancreas"},{"key":"56268_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52\u201367 (2010).","journal-title":"Cell"},{"key":"56268_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1042\/BJ20111240","volume":"441","author":"MA Shields","year":"2012","unstructured":"Shields, M. A., ngi-Garimella, S., Redig, A. J., Munshi, H. G. & Dangi-Garimella, S. Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem.J. 441, 541\u2013552 (2012).","journal-title":"Biochem.J."},{"key":"56268_CR18","doi-asserted-by":"publisher","first-page":"7427","DOI":"10.1158\/1078-0432.CCR-03-0825","volume":"10","author":"T Armstrong","year":"2004","unstructured":"Armstrong, T. et al. Type I Collagen Promotes the Malignant Phenotype of Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res. 10, 7427\u20137437 (2004).","journal-title":"Clin. Cancer Res."},{"key":"56268_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/00006676-199511000-00007","volume":"11","author":"T Imamura","year":"1995","unstructured":"Imamura, T. et al. Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic pancreatitis, and alcoholic chronic pancreatitis. Pancreas 11, 357\u201364 (1995).","journal-title":"Pancreas"},{"key":"56268_CR20","unstructured":"Menke, A. et al. Down-Regulation of E-Cadherin Gene Expression by Collagen Type I and Type III in Pancreatic Cancer Cell Lines. Biochemistry 61, 3508\u20133517 (2001)."},{"key":"56268_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/1471-2407-13-154","volume":"13","author":"D \u00d6hlund","year":"2013","unstructured":"\u00d6hlund, D. et al. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer 13, 154 (2013).","journal-title":"BMC Cancer"},{"key":"56268_CR22","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1101\/gad.279737.116","volume":"30","author":"P Gascard","year":"2016","unstructured":"Gascard, P. & Tlsty, T. D. Carcinoma-associated fibroblasts: Orchestrating the composition of malignancy. Genes Dev. 30, 1002\u20131019 (2016).","journal-title":"Genes Dev."},{"key":"56268_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.addr.2015.11.001","volume":"97","author":"AD Theocharis","year":"2016","unstructured":"Theocharis, A. D., Skandalis, S. S., Gialeli, C. & Karamanos, N. K. Extracellular matrix structure. Adv. Drug Deliv. Rev. 97, 4\u201327 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"56268_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat.Rev.Cancer 6, 392\u2013401 (2006).","journal-title":"Nat.Rev.Cancer"},{"key":"56268_CR25","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582\u2013598 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"56268_CR26","doi-asserted-by":"crossref","unstructured":"Willumsen, N. et al. Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls. BMC Cancer 13, 554 (2013).","DOI":"10.1186\/1471-2407-13-554"},{"key":"56268_CR27","first-page":"257","volume":"17","author":"A Roy","year":"1998","unstructured":"Roy, A. et al. Phase 3 trial of SMS 201-995 pa LAR (SMS PA LAR) and continuous infusion 5FU in unresectable stage II, III, and IV pancreatic cancer. Proc Am Soc Clin Oncol 17, 257 (1998).","journal-title":"Proc Am Soc Clin Oncol"},{"key":"56268_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12029-013-9564-9","volume":"45","author":"A Alkhateeb","year":"2014","unstructured":"Alkhateeb, A. et al. Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease. J. Gastrointest. Cancer 45, 161\u2013167 (2014).","journal-title":"J. Gastrointest. Cancer"},{"key":"56268_CR29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3109\/1354750X.2011.620628","volume":"16","author":"D Leeming","year":"2011","unstructured":"Leeming, D. et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 16, 616\u2013628 (2011).","journal-title":"Biomarkers"},{"key":"56268_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.clinbiochem.2010.03.012","volume":"43","author":"N Barascuk","year":"2010","unstructured":"Barascuk, N. et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin. Biochem. 43, 899\u2013904 (2010).","journal-title":"Clin. Biochem."},{"key":"56268_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1755-1536-4-22","volume":"4","author":"SS Veidal","year":"2011","unstructured":"Veidal, S. S. et al. Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis.Tissue Repair. 4, 22 (2011).","journal-title":"Fibrogenesis.Tissue Repair."},{"key":"56268_CR32","first-page":"303","volume":"5","author":"MJ Nielsen","year":"2013","unstructured":"Nielsen, M. J. et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am. J. Transl. Res. 5, 303\u2013315 (2013).","journal-title":"Am. J. Transl. Res."},{"key":"56268_CR33","doi-asserted-by":"publisher","first-page":"e0194458","DOI":"10.1371\/journal.pone.0194458","volume":"13","author":"SN Kehlet","year":"2018","unstructured":"Kehlet, S. N. et al. Age-related collagen turnover of the interstitial matrix and basement membrane: Implications of age- and sex-dependent remodeling of the extracellular matrix. PLoS One 13, e0194458 (2018).","journal-title":"PLoS One"},{"issue":"5","key":"56268_CR34","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/cam4.303","volume":"3","author":"Nicholas Willumsen","year":"2014","unstructured":"Willumsen, N. et al. Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer. Cancer Med. 3, 1136\u20131145.","journal-title":"Cancer Medicine"},{"issue":"6","key":"56268_CR35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3233\/CBM-150520","volume":"15","author":"C.L. Bager","year":"2015","unstructured":"Bager, C. L. et al. Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: A preliminary study. Cancer Biomark. 15, 783\u2013788 (2015).","journal-title":"Cancer Biomarkers"},{"key":"56268_CR36","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1002\/ijc.31627","volume":"143","author":"A Lipton","year":"2018","unstructured":"Lipton, A. et al. High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. Int. J. Cancer 143, 3027\u20133034 (2018).","journal-title":"Int. J. Cancer"},{"key":"56268_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0474-z","volume":"6","author":"C Jensen","year":"2018","unstructured":"Jensen, C. et al. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti- CTLA-4) in metastatic melanoma patients. J. Immunother. Cancer 6, 1\u201310 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"56268_CR38","doi-asserted-by":"crossref","unstructured":"Chen, I. et al. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. Int. J. Cancer\u00a0(2019).","DOI":"10.1002\/ijc.32751"},{"key":"56268_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13046-019-1110-6","volume":"38","author":"NI Nissen","year":"2019","unstructured":"Nissen, N. I., Karsdal, M. & Willumsen, N. Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology. J. Exp. Clin. Cancer Res. 38, 115 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"56268_CR40","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano, P. P. et al. Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma. Cancer Cell 21, 418\u2013429 (2012).","journal-title":"Cancer Cell"},{"key":"56268_CR41","doi-asserted-by":"crossref","unstructured":"Wong, K. M., Horton, K. J., Coveler, A. L., Hingorani, S. R. & Harris, W. P. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20). Curr. Oncol. Rep. 19 (2017).","DOI":"10.1007\/s11912-017-0608-3"},{"key":"56268_CR42","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","volume":"36","author":"SR Hingorani","year":"2018","unstructured":"Hingorani, S. R. et al. HALO 202: Randomized phase II Study of PEGPH20 Plus Nab-Paclitaxel\/Gemcitabine Versus Nab-Paclitaxel\/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J. Clin. Oncol. 36, 359\u2013366 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"56268_CR43","doi-asserted-by":"publisher","first-page":"12030","DOI":"10.1200\/JCO.2018.36.15_suppl.12030","volume":"36","author":"Song Wang","year":"2018","unstructured":"Wang, S. et al. Extracellular matrix (ECM) circulating peptide biomarkers as potential predictors of survival in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (mPDA) receiving pegvorhyaluronidase alfa (PEGPH20), nab-paclitaxel (A), and gemcitabine (G). J. Clin. Oncol. 36, 12030 (2018).","journal-title":"Journal of Clinical Oncology"},{"key":"56268_CR44","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1158\/0008-5472.CAN-18-3751","volume":"79","author":"H Huang","year":"2019","unstructured":"Huang, H. & Brekken, R. A. The next wave of stroma-targeting therapy in pancreatic cancer. Cancer Res. 79, 328\u2013330 (2019).","journal-title":"Cancer Res."},{"key":"56268_CR45","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/0008-5472.CAN-18-1334","volume":"79","author":"KY Elahi-Gedwillo","year":"2019","unstructured":"Elahi-Gedwillo, K. Y., Carlson, M., Zettervall, J. & Provenzano, P. P. Antifibrotic therapy disrupts stromal barriers and modulates the immune landscape in pancreatic ductal adenocarcinoma. Cancer Res. 79, 372\u2013386 (2019).","journal-title":"Cancer Res."},{"key":"56268_CR46","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1053\/j.gastro.2017.11.280","volume":"154","author":"C Vennin","year":"2018","unstructured":"Vennin, C. et al. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. Gastroenterology 154, 820\u2013838 (2018).","journal-title":"Gastroenterology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56268-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56268-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56268-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:15:27Z","timestamp":1695550527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56268-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,24]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["56268"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-56268-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,24]]},"assertion":[{"value":"5 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nicholas Willumsen and Morten A. Karsdal have declared financial competing interest from employment at Nordic Bioscience involved in biomarker discovery and development. All remaining authors have declared no financial conflicts of interest. None of the authors have non-financial competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19761"}}